Please login to the form below

Not currently logged in
Email:
Password:

Galapagos awarded milestone payment from Boehringer Ingelheim

Belgium based genomic drug discovery company Galapagos has revealed that its BioFocus DPI service division received a milestone payment in the autoimmune discovery research collaboration with Boehringer Ingelheim.

Belgium based genomic drug discovery company Galapagos has revealed that its BioFocus DPI service division received a milestone payment in the autoimmune discovery research collaboration with Boehringer Ingelheim.

The three-year collaboration announced in January 2006 involves an expansion of BioFocus DPI's SilenceSelect RNA based gene collection with an additional gene set, the development of a dedicated cellular assay in the field of autoimmune diseases, and its application in a target discovery screen for Boehringer Ingelheim's autoimmune discovery research.

Galapagos obtained upfront fees and will continue to receive R&D funding, and will receive milestone fees when certain drug discovery criteria are met. Should all criteria on a target be achieved, total potential contract value for Galapagos coudl exceed EUR 2m (USD 2.7m).

Onno van de Stolpe, CEO of Galapagos, said: "This milestone speaks to BioFocus DPI's ability to deliver on longer term, higher value collaborations. We are delighted that the collaboration with Boehringer Ingelheim has progressed as planned and is on track to continue delivering value."

25th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics